[Peroral ciprofloxacin in the therapy of infections in oncology patients].
The authors give an account of their initial experience with oral ciprofloxacin (Ciprinol) in the treatment of various infections in 28 immunosuppressed oncological patients. A favourable effect--cure and improvement--were recorded in 72% of all treated patients. Unfavourable side-effects were observed in 4 of 28 patients, in two they were the reason for discontinuation of treatment.
Krcméry
V
V
Katedra klinickej onkológie ILF, Bratislava.
Horníková
M
M
Koza
I
I
Fuchsberger
P
P
Spánik
S
S
Sufliarsky
J
J
Mardiak
J
J
Sitáni
L
L
Milosovic
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*
D002939:Ciprofloxacin
Perorálny ciprofloxacín v liecbe infekcií u onkologických pacientov.